With current findings, FcγR polymorphisms, especially FcγRIIa-131H/H, can be a useful tool for selecting candidates for treatment with anti-EGFR inhibitors in mCRC and HNSCC. Here, EGFR is linked to head and neck squamous cell carcinoma.